These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 9458985

  • 1. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
    Pfaller MA, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):273-6. PubMed ID: 9458985
    [Abstract] [Full Text] [Related]

  • 2. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
    Pfaller MA, Jones RN, Marshall SA, Edmond MB, Wenzel RP.
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):259-63. PubMed ID: 9458983
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci.
    Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 1997 Apr; 27(4):151-4. PubMed ID: 9154412
    [Abstract] [Full Text] [Related]

  • 7. Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients.
    Piérard D, de Meyer A, Lauwers S.
    Pathol Biol (Paris); 1994 May; 42(5):471-4. PubMed ID: 7824316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
    Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, Wenzel RP.
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility of viridans group streptococci.
    Tuohy M, Washington JA.
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):277-80. PubMed ID: 9458986
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.
    Low DE, de Azavedo J, Canadian Bacterial Surveillance Network, Davidson R.
    Can J Infect Dis; 1999 Mar; 10(2):122-7. PubMed ID: 22346377
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.
    Marshall SA, Wilke WW, Chen YS, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 1998 Jan; 30(1):65-9. PubMed ID: 9488834
    [Abstract] [Full Text] [Related]

  • 16. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
    Paulus S, Dobson S, Rassekh S, Blondel-Hill E.
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):267-9. PubMed ID: 19346878
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ.
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
    Kuriyama T, Karasawa T, Nakagawa K, Nakamura S, Yamamoto E.
    Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.